Abstract
The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state.
Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72.
The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.
Key words: Nicotine, Rhinitis, pharmacokinetics, nasal spray, xylometazoline, drug interaction
References
- 1.Pontiroli AE, Calderara A, Pozza G. Intranasal Drug Delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective. Clin Pharmacokinet. 1989;17:299–307. doi: 10.2165/00003088-198917050-00001. [DOI] [PubMed] [Google Scholar]
- 2.Russel MAH, Jarvis MJ, Feyerabend C. A new age for snuff? Lancet. 1980;I:474–475. doi: 10.1016/s0140-6736(80)91010-7. [DOI] [PubMed] [Google Scholar]
- 3.Russel MAH, Jarvis MJ, Feyerabend C, Fernö O. Nasal nicotine solution: a potential aid to give up smoking? Br Med J. 1983;286:683–684. doi: 10.1136/bmj.286.6366.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Jarvis MJ, Hajek P, Russel MAH, West RJ, Feyerabend C. Nasal nicotine solution as an aid to cigarette withdrawal: a pilot clinical trial. Br J Addict. 1987;82:983–988. doi: 10.1111/j.1360-0443.1987.tb01558.x. [DOI] [PubMed] [Google Scholar]
- 5.Schneider NG. Nicotine therapy in smoking cessation. Pharmacokinetic considerations. Clin Pharmacokinet. 1992;23(3):169–172. doi: 10.2165/00003088-199223030-00001. [DOI] [PubMed] [Google Scholar]
- 6.Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. Arch Intern Med. 1958;101:267–278. doi: 10.1001/archinte.1958.00260140099015. [DOI] [PubMed] [Google Scholar]
- 7.Olsson P, Kuylenstierna F, Johansson C-J, Gunnar PO, Bende M. Pharmacokinetics of nicotine after intranasal administration. In: Adlkofer F, editor. Effects of nicotine on biological systems. Advances in pharmacologica sciences. Basel: Birkhäuser; 1991. pp. 57–61. [Google Scholar]
- 8.Sutherland G, Stapleton JA, Russell MAH, et al. Randomised controlled trial of nicotine nasal spray in smoking cessation. Lancet. 1992;340:324–329. doi: 10.1016/0140-6736(92)91403-u. [DOI] [PubMed] [Google Scholar]
- 9.Hjalmarsson A, Franzon M, Westin Å, Wiklund O. Effect of nicotine nasal spray in smoking cessation. A randomised, placebo-controlled, double-blind study. Arch Int Med. 1994;154:2567–2572. [PubMed] [Google Scholar]
- 10.Greiff L, Wollmer P, Svensson C, Andersson M, Persson CGA. Effect of seasonal allergic rhinitis on airway mucosal absorption of chromium-51 labelled EDTA. Thorax. 1993;48:648–650. doi: 10.1136/thx.48.6.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Greiff L, Svensson C, Andersson M, Åkerlund A, Wollmer P, Alkner U, Persson CGA. Increased exudative responsiveness in allergen and corona virus-induced airway inflammation. Allergy. 1993;48:91. [Google Scholar]
- 12.Persson CGA, Erjefält I, Alkner U, Baumgarten C, Greiff L, Gustafsson B, et al. Plasma exudation as a first line respiratory mucosal defence. Clin Exp Allergy. 1991;21:17–24. doi: 10.1111/j.1365-2222.1991.tb00799.x. [DOI] [PubMed] [Google Scholar]
- 13.Bende M. The effect of topical decongestant on blood flow in normal and infected nasal mucosa. Acta Otolaryngol (Stockh) 1983;96:523–527. doi: 10.3109/00016488309132740. [DOI] [PubMed] [Google Scholar]
- 14.Russell MAH, et al. In: Tobacco smoking and nicotine dependence. Gibbins, et al., editors. New York: Wiley; 1976. pp. 1–47. [Google Scholar]